ANG Lifesciences India Ltd
Incorporated in 2006, ANG Lifesciences
India Ltd is in the business of pharmaceuticals products & formulations, and packaging and printing.[1]
- Market Cap ₹ 42.9 Cr.
- Current Price ₹ 32.8
- High / Low ₹ 49.7 / 17.6
- Stock P/E
- Book Value ₹ 40.5
- Dividend Yield 0.00 %
- ROCE -2.32 %
- ROE -16.5 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.81 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -9.66% over past five years.
- Company has a low return on equity of -14.4% over last 3 years.
- Promoters have pledged 44.9% of their holding.
- Company has high debtors of 267 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| 154 | 354 | 220 | 145 | 93 | 93 | 84 | |
| 140 | 286 | 205 | 135 | 94 | 90 | 85 | |
| Operating Profit | 14 | 68 | 15 | 10 | -1 | 3 | -2 |
| OPM % | 9% | 19% | 7% | 7% | -1.6% | 2.8% | -2.2% |
| 1 | 1 | 10 | -1 | 2 | -1 | 1 | |
| Interest | 4 | 9 | 12 | 11 | 9 | 8 | 8 |
| Depreciation | 1 | 6 | 9 | 8 | 7 | 6 | 6 |
| Profit before tax | 10 | 54 | 3 | -11 | -16 | -13 | -16 |
| Tax % | 31% | 25% | 110% | -5% | -21% | -15% | |
| 7 | 40 | -0 | -10 | -12 | -11 | -13 | |
| EPS in Rs | 5.26 | 31.02 | -0.20 | -7.77 | -9.50 | -8.49 | -10.21 |
| Dividend Payout % | 0% | 3% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -10% |
| 3 Years: | -25% |
| TTM: | -16% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -17% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -41% |
| 3 Years: | -22% |
| 1 Year: | 0% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | -14% |
| Last Year: | -16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 10 | 13 | 13 | 13 | 13 | |
| Reserves | 73 | 73 | 63 | 51 | 40 | |
| 77 | 71 | 73 | 83 | 79 | ||
| 130 | 119 | 92 | 82 | 78 | ||
| Total Liabilities | 290 | 276 | 241 | 230 | 210 | |
| 93 | 88 | 58 | 57 | 51 | ||
| CWIP | 0 | 0 | 0 | 0 | 0 | |
| Investments | 0 | 0 | 0 | 0 | 0 | |
| 198 | 188 | 183 | 172 | 160 | ||
| Total Assets | 290 | 276 | 241 | 230 | 210 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 25 | 26 | -9 | -0 | 11 | ||
| -44 | -9 | 20 | -2 | 1 | ||
| 20 | -17 | -10 | 2 | -12 | ||
| Net Cash Flow | 0 | -0 | -0 | -0 | 0 | |
| Free Cash Flow | -17 | 16 | 9 | -4 | 11 | |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 37% | 202% | 39% | -272% | 429% |
Ratios
Consolidated / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 105 | 138 | 184 | 262 | 267 | |
| Inventory Days | 59 | 118 | 183 | 331 | 288 | |
| Days Payable | 113 | 165 | 254 | 405 | 317 | |
| Cash Conversion Cycle | 51 | 91 | 113 | 189 | 238 | |
| Working Capital Days | 20 | 24 | 58 | 72 | -8 | |
| ROCE % | 9% | 1% | -4% | -2% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Export revenue (domiciled outside India) Rs Lakhs ・Standalone data |
|
|||||||||||
| Capacity Utilization of Dry Powder Vials % ・Standalone data |
||||||||||||
| Number of permanent employees count ・Standalone data |
||||||||||||
| Production volume of Dry Powder Vials Lakhs Pieces ・Standalone data |
||||||||||||
| Number of countries exporting to count ・Standalone data |
||||||||||||
| Order book position Rs crore ・Standalone data |
||||||||||||
| Revenue share - Government Institutions % of total revenue ・Standalone data |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Submitted Regulation 74(5) certificate for quarter ended 30 September 2026.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
-
Announcement under Regulation 30 (LODR)-Change in Management
- Members approved Mrs. Chetna’s reappointment as Independent Director for five years from October 12, 2026 to October 11, 2031.
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
- ANG Lifesciences held its 20th AGM on 30 September 2026; approved financials, director reappointment, and cost auditor ratification.
- Closure of Trading Window
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
Business Overview:[1][2][3]
ANGLIL is a part of the ANG Group which is a WHO-GMP–certified consortium of pharmaceutical companies. The company is engaged in the manufacturing of pharmaceuticals & allied products which include finished formulations in Non-Beta Lactam, Beta Lactam, Cephalosporin, and Carbapenem segments.